(Q58204744)

2

0 references

Shigeto Tohma

3

0 references

Tsutomu Takeuchi

4

0 references

Hirobumi Kondo

5

0 references

Hitoshi Kohsaka

6

0 references

Shoichi Ozaki

7

0 references

Hiroshi Hashimoto

8

0 references

Nobuyuki Miyasaka

9

0 references

Ami Yamamoto

10

0 references

Masaki Hiraoka

11

0 references

Tohru Abe

https://scigraph.springernature.com/pub.10.1007/s10165-012-0722-x

12

0 references

publication date

26 July 2012

0 references

published in

Modern Rheumatology

0 references

volume

23

0 references

issue

4

0 references

page(s)

634-645

0 references

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Therapeutic strategies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X

Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10165-012-0722-X